Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty

Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty Purpose of Review Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices. Recent Findings The cost of therapy for CLL has increased substantially since the introduction of oral therapies. This increase in cost is caused by multiple factors including cost of drug development, alternate reimbursement patterns, lack of transparency, and lack of free market competition. Summary Oral therapies for CLL have dramatically increased costs for both patients and payers. Some solutions to overcome this include value-based pricing, transparency, and legal action that allow Medicare to negotiate drug prices with manufacturers. . . . . . Keywords CLL Ibrutinib Idelalisib Venetoclax Drug costs Pharmacoeconomics, financial toxicity Introduction PFS of 4.2 years [6], while those with del(17p) have a median PFS of 1 year [3]. Chronic lymphocytic leukemia (CLL) is the most com- B cell receptor signaling plays a central role in disease path- mon leukemia in the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hematologic Malignancy Reports Springer Journals

Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/economic-impact-of-oral-therapies-for-chronic-lymphocytic-leukemia-the-ultdrIj7T4

References (39)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
ISSN
1558-8211
eISSN
1558-822X
DOI
10.1007/s11899-018-0461-y
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices. Recent Findings The cost of therapy for CLL has increased substantially since the introduction of oral therapies. This increase in cost is caused by multiple factors including cost of drug development, alternate reimbursement patterns, lack of transparency, and lack of free market competition. Summary Oral therapies for CLL have dramatically increased costs for both patients and payers. Some solutions to overcome this include value-based pricing, transparency, and legal action that allow Medicare to negotiate drug prices with manufacturers. . . . . . Keywords CLL Ibrutinib Idelalisib Venetoclax Drug costs Pharmacoeconomics, financial toxicity Introduction PFS of 4.2 years [6], while those with del(17p) have a median PFS of 1 year [3]. Chronic lymphocytic leukemia (CLL) is the most com- B cell receptor signaling plays a central role in disease path- mon leukemia in the

Journal

Current Hematologic Malignancy Reports – Springer Journals

Published: Jul 7, 2018

There are no references for this article.